Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Common Equity (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Common Equity for 8 consecutive years, with $16.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 74.36% to $16.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.6 million, a 74.36% decrease, with the full-year FY2024 number at $56.4 million, up 198.99% from a year prior.
  • Common Equity was $16.6 million for Q3 2025 at Precision Biosciences, down from $34.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $103.0 million in Q2 2022 to a low of $16.6 million in Q3 2025.
  • A 5-year average of $59.2 million and a median of $58.8 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 198.99% in 2024, then crashed 74.36% in 2025.
  • Precision Biosciences' Common Equity stood at $91.2 million in 2021, then tumbled by 33.71% to $60.4 million in 2022, then plummeted by 68.79% to $18.9 million in 2023, then surged by 198.99% to $56.4 million in 2024, then plummeted by 70.5% to $16.6 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Common Equity are $16.6 million (Q3 2025), $34.1 million (Q2 2025), and $49.3 million (Q1 2025).